Skip to content

Clinical trials

Coronary Artery Disease trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Coronary Artery Disease Phase: Not applicable Country / region: United States Clear all

348 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20005
20011
20024
20033
20041
20057
200613
200718
200818
200916
201020
201115
201219
201314
201423
201519
201614
201715
201820
201913
20208
202110
202210
202314
202416
202515
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed214
Terminated40
Recruiting26
Active, not recruiting24
Unknown status20
Not yet recruiting9
Withdrawn9
Enrolling by invitation5
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Abbott Medical Devices22
Medtronic Vascular12
Johns Hopkins University10
Emory University9
Massachusetts General Hospital8
Mayo Clinic8
University of Florida7
Brigham and Women's Hospital6
Cedars-Sinai Medical Center6
Indiana University6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Coronary Artery Disease348
Cardiovascular Diseases35
Myocardial Infarction32
Myocardial Ischemia32
Diabetes Mellitus27
Atherosclerosis26
Heart Failure26
Heart Diseases23
Coronary Disease21
Hypertension19

Trials

Showing 1 to 25 of 348. Each trial links to its page on Pharma Observatory.

248 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.